Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Commercial plans.

When does this change take effect?

This change is effective Nov 17, 2025.

Back to dashboard

CommercialPrior AuthMedium impact

08.01.11j, Ado-Trastuzumab Emtansine (Kadcyla®)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Nov 17, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

IBX updated their medical necessity criteria and coding requirements for Ado-Trastuzumab Emtansine (Kadcyla), a cancer medication used primarily for HER2-positive breast cancer. This affects billing and prior authorization requirements for oncology practices administering this specialized chemotherapy drug.

Action Required

Action needed

By November 17, 2025: Oncology billing teams must review updated medical necessity criteria for Kadcyla (Ado-Trastuzumab Emtansine) claims. Update prior authorization workflows and ensure documentation meets new IBX requirements. Review coding changes that may affect claim submission for this cancer medication.

Related policy hubs

Independence Blue Cross policies Oncology Hematology